Abstract: Fatty amine compositions made from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives are disclosed. In another aspect, fatty amidoamines made by reacting a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with an aminoalkyl-substituted tertiary amine are disclosed. The fatty amines or amidoamines are advantageously sulfonated, sulfitated, oxidized, or reduced. In other aspects, the ester derivative is a modified triglyceride made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin.

Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.

Abstract: The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides.

Abstract: This invention provides a process for producing a high-purity sphingomyelin and a high-purity plasmalogen-form glycerophospholipid from a biological material by simple procedures at high yields.

Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.

Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Abstract: The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker.

Abstract: This invention provides a process for producing a high-purity sphingomyelin and a high-purity plasmalogen-form glycerophospholipid from a biological material by simple procedures at high yields.

Abstract: The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.

Abstract: Novel amides of polyunsaturated fatty acids with cysteamine-S-phosphate have been synthesized. Combinations of the all-trans-retinoic acid and/or amides of the 13-cis-retinoic acid with O-phospho-L-tyrosine, and N-docosahex-aenoyl-cysteamine-S-phosphate, N-eicosapentaenoyl-cysteamine-S-phosphate, N-arachidonoyl-cysteamine-S-phosphate, N-&agr;-linolenoyl-cysteamine-S-phosphate, and N-&ggr;-linolenoyl-cysteamine-S-phosphate and their analogues N-docosahex-aenoyl-O-phospho-2-aminoethanol, N-eicosapentaenoyl-O-phospho-2-aminoethanol, N-arachidonoyl-O-phospho-2-aminoethanol, N-&agr;-linolenoyl-O-phospho-2-aminoethanol, N-&ggr;-linolenoyl-O-phospho-2-aminoethanol in different compositions exhibit a marked cell-growth inhibiting effect and display anti-tumour activity.

Abstract: The present invention relates to novel compounds and, more particularly, to a class of compounds having specific quatenized amine based upon a castor amido amine linked to specific phosphate esters. Castor oil contains predominantly ricinoleic moiefies. This phospholipid is an excellent emulsifier, conditioner and provides foam in formulations. It is also substantitive to human skin and is well tolerated by human tissue making it suitable for use in personal care applications.

Abstract: The present invention concerns new lipid derivatives of phosphonocarboxylic acids of the general formula I, ##STR1## in which the meaning of the symbols is elucidated in the description, tautomers thereof and their physiologically tolerated salts of inorganic and organic bases as well as processes for the production thereof and pharmaceutical agents containing these compounds.

Abstract: Novel (o-acyl-p-N-acylamino-phenyl)-O-phosphoethanolamines and pharmaceutically acceptable salts thereof having anti-inflammatory activity, and pharmaceutical compositions containing same are disclosed. Certain novel intermediates are also disclosed.

Abstract: An efficient method of producing phytosphingosine-containing ceramide one comprising: (a) obtaining a phytosphingosine base from tetraacetylphytosphingosine (TAPS) by a deacetylation reaction wherein the TAPS is produced by fermentation of cells of the F-60-10 mating type strain of Hansenula ciferrii using a fed-batch mode and a non-fermentable carbon source; and (b) coupling together the phytosphingosine base and a fatty acid/.omega.-hydroxy fatty acid component wherein the .omega.-hydroxy fatty acid component is prepared by a process which includes Kolbe synthesis.

Abstract: Modified ceramides are defined, together with their synthesis and compositions comprising them for topical application to human skin, hair and nails. The modified pseudoceramides have a structure: ##STR1## and an approximate summary is that R and R.sup.1 are aliphatic hydrocarbon, A is CH.sub.2, CHOR.sup.2, CH.dbd.CH or CHOY, and at least one of R.sup.2, R.sup.3 and R.sup.4 is sulphate, phosphate or similar. The presence of phosphate or sulphate facilitates skin absorption, after which the phosphate or sulphate is removed by enzymes present in vivo.

Abstract: The process described relates to the preparation of aqueous betaine solutions by reaction of a tertiary amine with an .omega.-monohalocarboxylic acid, preferably monochloroacetic acid, and an alkali metal hydroxide in the presence of water, which solutions are said to be highly pure particularly in respect of the tertiary starting amine and .omega.-monohalocarboxylic acid. This is achieved by first reacting the three reaction components in a certain molar ratio with the aim of obtaining a betaine solution which comprises only a tolerated amount of starting amine. This aqueous betaine solution is then treated with a sulfonating agent, preferably with an alkali metal sulfite, alkali metal pyrosulfite or alkali metal bisulfite, for conversion of the .omega.-monohalocarboxylic acid present into the corresponding sulfocarboxylic acid, which is not troublesome. The process described is simple to carry out and leads to the highly pure aqueous betaine solutions mentioned.

Abstract: A modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linking group and a pharmaceutical composition comprising the modified biologically active protein in a pharmaceutically acceptable carrier. The biologically active proteins include antibodies, superoxide dismutase, insulin and callidinogenase. Lecithin derivatives are also disclosed.

Abstract: A method is disclosed for the preparation of flowable, aqueous dispersions, which contain 10 to 30% by weight of betaines of the general formula ##STR1## wherein R.sup.1 is a linear alkyl group with at least 16 carbon atoms or the R.sup.4 CONH(CH.sub.2).sub.x -- group, in which R.sup.4 CO is an acyl group derived from a saturated, linear fatty acid with at least 16 carbon atoms and x=2 or 3,R.sup.2, R.sup.3 are the same or different and in each case represent an alkyl group with 1 to 4 carbon atoms,y is 1, 2 or 3,by quaternizing a tertiary amine of the general formulaR.sup.1 --NR.sup.2 R.sup.3with .omega.-halogenalkylcarboxylic acids X(CH.sub.2).sub.y COOY or their salts (X=halogen group, Y=hydrogen, alkali or ammonium) in an aqueous or alcoholic, aqueous solution at elevated temperature. Anionic surfactants are added to the reaction mixture before the quaternization reaction in such amounts, that the ultimate dispersion contains 1 to 10% by weight of anionic surfactants.